Abstract
AbstractBackgroundEnterotoxigenicEscherichia coli(ETEC) is one of the leading bacterial causes of intestinal inflammation and diarrhea. However, the ETEC is frequently resistant to common antibiotics. In this study, we explored the role of a novel antibacterial peptideBombyx morigloverin A2 (BMGlvA2) in alleviating ETEC-induced inflammation and intestinal epithelium disruption in mice.MethodsAn ETEC-challenged mice model was used, and the ETEC-challenged mice and non-challenged mice were treated by the BMGlvA2 at different doses.ResultsETEC challenge not only elevated the concentrations of serum inflammatory cytokines such as the IL-6 and TNF-α (P < 0.01), but also elevated the concentrations of serum creatinine and urea (P < 0.05). However, BMGlvA2 attenuated the inflammatory responses by decreasing the serum inflammatory cytokines and improving the metabolisms in ETEC-challenged mice, and alleviated the ETEC-induced tissue damage in spleen. Moreover, BMGlvA2 treatment significantly elevated the duodenum villus height and decreased the crypt depth in the duodenum and ileum in ETEC-challenged mice (P < 0.05). Interestingly, BMGlvA2 improved the distribution and abundance of tight-junction protein ZO1 in duodenum and ileum epithelium after ETEC-challenge. Moreover, BMGlvA2 significantly down-regulated the expression levels of inflammatory cytokines (IL-1β, IL-6, and TNF-α) and the apoptosis-related genes (Caspase 8 and Caspase 9) in jejunal mucosa (P < 0.05) in the TETC-challenged mice. Importantly, BMGlvA2 significantly elevated the expression levels of critical genes related to mucosal barrier functions such as the mucins (MUC1 and MUC2) and glucose transporter (GLUT2) in the intestinal mucosa (P < 0.05).ConclusionOur results suggested a novel function of the conventional antibacterial peptides, and the anti-bacterial and anti-inflammatory properties of BMGlvA2 may allow it a potential substitute for conventionally used antibiotics or drugs.
Funder
the Key Research and Development Program of Sichuan Province
the Youth Innovation teams of Animal Feed Biotechnology of Sichuan Province
Opening fund of Key Laboratory for Innovative Development and Utilization of Forest Plant Germplasm.
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Infectious Diseases,Microbiology (medical),Public Health, Environmental and Occupational Health
Reference64 articles.
1. Nagy B, Fekete PZ. Enterotoxigenic Escherichia coli in veterinary medicine. J Med Microbiol. 2005;295(6–7):0–454.
2. Sack RB. Human diarrheal disease caused by enterotoxigenic Escherichia coli. Annu Rev Microbiol. 1975;29(1):333–54.
3. Zhang HH, You JS, Xu YP, Wang XL, Li XY. China Animal Husbandry & Veterinary Medicine. 2015;42(2):347–351.
4. Schmidt H, Secchi A, Wellmann R, Bach A, Böhrer H, Gebhard MM, et al. Journal of Surgical Research. 1996;61(2):521–526.
5. Gupta M, Kumar A. Comparison of minimum inhibitory concentration (MIC) value of statin drugs: a systematic review. Anti Infect Agents. 2019;17(1):4–19.
Cited by
19 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献